Shenlian Biotech (688098.SH) announced semi-annual results, with a net loss of 19.1464 million yuan

Zhitong Finance App News, Shenlian Biotech (688098.SH) released its 2026 semi-annual report. During the reporting period, the company achieved operating income of 112 million yuan, a year-on-year decrease of 8.05%; net loss attributable to shareholders of listed companies of 19.1464 million yuan; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 19.15,800 yuan; basic earnings per share - 0.05 yuan.

During the reporting period, in an external environment where competition in the industry intensified, the company seized structural development opportunities, actively grasped customer needs, and continued to increase market development efforts; further optimized internal management mechanisms and strengthened cost control. All expenses declined year-on-year. However, due to the application of value-added tax rate adjustments to biological products, although the company's pre-VAT revenue increased compared to the same period last year, post-tax revenue declined slightly. At the same time, due to factors such as revenue pressure, increased credit impairment losses, and clinical promotion of innovative drugs, the scale of net profit losses attributable to owners of the parent company increased slightly compared to the same period last year. Excluding the impact of changes in the value-added tax rate for biological products in the first half of the year, according to simulated estimates for the same period last year, both operating income and net profit increased slightly year-on-year during the reporting period.